Response to nivolumab as an immune checkpoint inhibitor rechallenge for esophageal squamous cell carcinoma with PD-L1 amplification: a case report
Therapeutic Advances in Medical Oncology
Published online on June 17, 2026
Abstract
Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
TheProgrammed death-ligand 1 (PD-L1)gene amplification has been proposed as a potential predictive biomarker for the efficacy of immune checkpoint inhibitors (ICIs); however, its clinical relevance in the setting of ICI rechallenge after resistance to ...
TheProgrammed death-ligand 1 (PD-L1)gene amplification has been proposed as a potential predictive biomarker for the efficacy of immune checkpoint inhibitors (ICIs); however, its clinical relevance in the setting of ICI rechallenge after resistance to ...